β -oxidation (FAO) is the main bioenergetic pathway in prostate cancer (PCa) and a promising novel therapeutic vulnerability. Here we demonstrate therapeutic efficacy of targeting FAO in clinical prostate tumors cultured ex vivo, and identify DECR1, which encodes the rate-limiting enzyme for oxidation of polyunsaturated fatty acids (PUFAs), as robustly overexpressed in PCa tissues and associated with shorter relapse-free survival.
Introduction
Prostate cancer (PCa) is the most prevalent male cancer and the second leading cause of cancer deaths in men in Western societies (1) . For patients with locally-recurrent and/or metastatic disease, androgen deprivation therapy (ADT) has remained the frontline strategy for clinical management since the 1940s (2) , due to the dependence of PCa cells on androgens for growth and survival. Although ADT is initially effective in most patients, ultimately all will relapse with castration resistant prostate cancer (CRPC), which remains incurable. The failure of ADT is attributed to the emergence of adaptive survival pathways that reprogram androgen signaling and/or activate alternative tumor survival pathways.
Consequently, the development and FDA approval of agents that more effectively target androgen signaling, including enzalutamide (ENZ, Xtandi; an AR antagonist) (3) (4) (5) , has expanded the therapeutic options for CRPC. Nevertheless, even these approaches cannot durably control tumor growth and there is considerable variability in the nature and duration of responses between different patients (3, 6, 7) . Thus, alternative therapeutic strategies that enhance response to ADT, and thereby prevent or delay PCa progression to CRPC, are essential.
Increasingly, targeting cancer cell metabolism is a focus of research efforts (8) . While fundamental differences in cellular metabolism pathways between normal and malignant cells were detected by Warburg in the 1920s (9) , clinical targeting of cancer metabolism has not kept pace with the research advances in understanding metabolic features of cancer cells. PCa is mainly dependent on lipid metabolism for energy production (10) . The overexpression of genes involved in lipid metabolism is characteristic of PCa at both early and advanced stages (11) (12) (13) (14) (15) (16) (17) , while recent proteomic analyses of primary PCa and bone metastases have shown clear associations between levels of lipid metabolic enzymes, PCa initiation and progression (18, 19) . These observations suggest that PCa may be particularly amenable to metabolic targeting strategies. Despite this, the role and complexity of lipid/fatty acid (FA) metabolism in PCa and its potential as a target for therapy remains underexplored, particularly in the context of a more complex tumor microenvironment.
Until recently, most attention has focused on the therapeutic targeting of de novo FA synthesis and, most recently, uptake of FAs in PCa to limit their availability as a source of energy and cell membrane phospholipids (14, 15, 20) . However, it has become evident in work from our group and others that β -oxidation of FAs, as the ultimate fate of FAs in the energy production cycle, is upregulated in PCa cells, stimulated by a lipid-rich extracellular environment and critical for viability (10, 21, 22) . In this study, we evaluated the targeting of FA β -oxidation (FAO) in patient-derived prostate tumor explants (PDE) to provide the first clinically-relevant evidence that targeting this pathway is efficacious. We subsequently identify DECR1, a rate-limiting enzyme in an auxiliary pathway for polyunsaturated fatty acid (PUFA) β -oxidation, as a promising novel therapeutic vulnerability for PCa.
Importantly, we show that DECR1 is an androgen-repressed gene induced in PCa cells in response to ADT and/or AR-targeted therapies, implicating PUFA oxidation as an adaptive survival response that may contribute to emergence of CRPC and treatment resistance.
Results

Targeting FA oxidation is efficacious in patient-derived PCa explants
In addition to our recent report of enhanced FAO in PCa cells (22) , an accumulating body of evidence supports the efficacy of targeting key enzymes involved in FAO using in vitro and in vivo models of PCa (23) (24) (25) . However, to date there is limited evidence that targeting this pathway would be clinically efficacious, which prompted us to target this pathway in clinical tumors. Using our well-defined patient derived explant (PDE) model that recapitulates the complexity of the clinical tissue microenvironment (26) , we targeted the rate-limiting enzyme in mitochondrial FAO, carnitine palmitoyltransferase-1 (CPT-1), in cultured PDEs using the chemical inhibitor etomoxir. Consistent with literature reports, etomoxir had weak activity against the LNCaP PCa cell line in vitro, with an IC50 of 170 µM ( Figure S1A ), but was considerably potent in the PDEs, in which a dose of 100 µM inhibited cell proliferation by an average of 48.4% ± 16.6% (n=13 patients; p<0.05) (Figure 1A) . Etomoxir effectively inhibited FAO in the tissues, evidenced by a significant decrease in multiple acylcarnitines in the conditioned medium ( Figure 1B) .
In order to prioritize key functional genes involved in PCa progression, we conducted a metaanalysis of the expression of 735 genes involved in lipid metabolism (as identified from REACTOME) in four clinical datasets with malignant and matched normal RNA sequencing data (27) (28) (29) . Genes were rank-ordered on the basis of their meta effect size scores in PCa malignant versus matched normal tissues ( Figure S1B ). The meta-analysis revealed a strikingly consistent deregulation of lipid metabolism genes, including genes involved in FAO (Figure 1C) , despite the predicted high inter-individual heterogeneity of patient PCa tissues. We conducted disease-relapse survival analysis using TCGA data for each of the top 7 20 genes from the meta-analysis. This identified DECR1 as a robustly overexpressed gene in PCa tissues that is associated with shorter relapse-free survival rates. 
Figure.1. Fatty acid
DECR1 is upregulated in clinical prostate tumors
Consistently, DECR1 mRNA expression was significantly higher in malignant compared to benign prostate tissues in ten independent expression datasets of PCa tissues versus nonmalignant tissues (Figure 1D , S1C). Further analysis of the TCGA data revealed increased DECR1 expression with increased Gleason score or in with advanced disease stage ( Figure   1E ). Consistent with our observation of increased DECR1 mRNA expression in PCa, DECR1
gene copy gain was evident in several clinical datasets accessed via cBioPortal (31) ( Figure   1F ). Interestingly, the top three cancer types exhibiting increased DECR1 copy gain were hormone-dependent tumors (uterine, breast and prostate), suggestive of a relationship between DECR1 expression and hormone signaling ( Figure 1G ). DECR1 mRNA expression was associated with shorter relapse-free survival rates and overall survival rates ( Figure 1H) , and in the TCGA dataset, DECR1 amplification was significantly associated with shorter recurrence-free survival rates ( Figure 1I) .
We confirmed overexpression of DECR1 protein in clinical PCa using two independent proteomic datasets (Figure 2A) . We observed overexpression of DECR1 in PCa tissues (n=8) compared with benign tissues (n=3) (Figure 2B) , and increased expression was evident in high grade versus low grade cancer tissue. Quantitative IHC staining analysis revealed a significant increase of DECR1 expression in malignant vs benign tissues. Furthermore, intratissue analysis exposed a significant increase of DECR1 expression in malignant regions vs benign ones within the same core ( Figure 2C ). DECR1 expression was markedly increased in a panel of hormone-dependent and -independent cancer cell lines compared with nonmalignant PNT1 and PNT2 prostate cell lines ( Figure 2D) . Consistent with its function, DECR1 localises to the mitochondria, confirmed using immunocytochemistry and Western blot of nuclear, cytoplasmic and mitochondrial cell fractions (Figure 2E) . Together, the mRNA and protein findings suggest that expression of DECR1 is closely linked to PCa progression and patient outcomes, and therefore might represent an unexplored therapeutic target. 
DECR1 is a directly androgen-repressed gene in PCa
The relationship between androgen receptor (AR) signaling and lipid metabolic genes is well established. Many studies have reported a marked stimulatory effect of AR on key lipid metabolism pathways either directly or indirectly through activation of a family of transcription factors called sterol regulatory element-binding proteins (SREBPs) (32) . We therefore investigated the relationship between AR and DECR1 using a panel of in vitro, ex vivo and in vivo models. DECR1 expression is notably more abundant in AR-negative cells (PC3) than in AR-expressing cells (Figure 2D) , consistent with negative regulation of DECR1 expression by AR. We confirmed that androgen (dihydrotestosterone) significantly decreased DECR1 expression in androgen-dependent LNCaP and VCaP cell lines at both mRNA and protein levels ( Figure 3A) . Data mining of publicly available microarray datasets also revealed downregulation of DECR1 in LNCaP cells after treatment with DHT or the synthetic androgen R1881 ( Figure S2A ; GSE7868, GSE22606). In contrast to the effect of androgens, AR-targeted therapies increase DECR1 expression. LNCaP and VCaP cell treatment with the androgen antagonist enzalutamide (ENZ) significantly increased DECR1 expression at both mRNA and protein levels ( Figure 3B) . In vivo, LNCaP tumors exhibit increased DECR1 expression in mice treated with ENZ (10 mg/kg) or castration, which was enhanced further in mice treated with both ENZ and castration ( Figure 3C) . Our observations were supported by published microarray datasets which showed that treatment of LNCaP or VCaP cells with ENZ increases DECR1 mRNA expression ( Figure S2B 
Targeting DECR1 suppresses PCa oncogenesis
The consistently increased expression of DECR1 in PCa tissue and its association with shorter-relapse times and survival rates (Figure 1 & 2) , taken together with its impact on PUFA metabolism (Figure 4) , Notably, this effect on PCa cell viability was lost when cells were cultured in lipid-depleted media ( Figure S4 ), suggesting that the observed effect is due to interference with FA metabolism. In contrast, stable DECR1 overexpression significantly enhanced LNCaP cell viability ( Figure 5B ) and colony formation ability (Figure 5C) , while stable DECR1 knockdown using a short hairpin vector markedly decreased colony formation (Figure 5D ).
DECR1 knockdown also decreased LNCaP growth in 3D spheroids (Figure 5E) , which better mimic in vivo conditions than 2-dimensional cell culture (36) . In addition, DECR1 knockdown reduced LNCaP, 22RV1 and MR49F cell migration by ~ 50% (Figure 5F ) and 22RV1 invasion by ~65% (Figure 5G) . LNCaP cells stably depleted of DECR1 showed highly variable growth rates in vivo, but inspection of the resultant tumors revealed significantly reduced cellular proliferation compared to control cells, concomitant with reduced DECR1 expression (Figure 5H, I) . (Figure 4) , which are highly susceptible to peroxidation, so we next assessed the effect of DECR1 knockdown on lipid peroxidation. DECR1 knockdown increased levels of malondialdehyde, a marker of lipid peroxidation (37) (Figure 6A) . In contrast, DECR1 overexpression markedly decreased cellular malondialdehyde levels (Figure 6A) . We observed enhanced mitochondrial oxidative stress measured using MitoSOX, a mitochondrial superoxide indicator (Figure 6B) , in response to DECR1 knockdown, while DECR1 overexpression significantly decreased mitochondrial oxidative stress under basal ( Figure   6C ) and linoleic acid-induced conditions (Figure 6D) . Lipid peroxidation is a major driver of ferroptosis, an iron-dependent non-apoptotic form of cell death (38) . Cell treatment with the ferroptosis inhibitor, ferrostatin, abolished the effect of DECR1 knockdown on PCa cell death ( Figure 6E) , while cell treatment with the ferroptosis inducer, erastin, enhanced the cytotoxic action of DECR1 downregulation (Figure 6F) . Collectively, these results suggest that DECR1 expression protect cells from oxidative stress and that DECR1 knockdown-induced cell death is mediated, at least partly, by induction of ferroptosis. (11, 39, 40) . While many first-generation FA synthesis inhibiters (e.g. FASN inhibitors)
showed promising preclinical efficacy against PCa, unfavourable drug solubility and pharmacokinetics profiles, off-target effects and side effects including weight loss have hindered clinical development of this agent class (14) . In addition to de novo synthesis of FAs, PCa cells depend on lipid uptake from the circulation, and from stromal adipocytes (20, 41, 42) . We showed previously that extracellular FAs are the major contributor to lipid synthesis in PCa (22) . Moreover, targeting FA uptake using an antibody against CD36, a major transporter for exogenous FAs into the cells, reduced cancer severity in patient-derived xenografts, and CD36 deletion slowed cancer progression in prostate-specific PTEN -/mice.
However, it is increasingly evident that PCa exhibits plasticity in attaining FAs and that crosstalk between de novo synthesis and FA uptake requires dual targeting of the two pathways to achieve maximal efficacy (20) , an approach that would likely be associated with greater toxicity. In this study, we focused on another understudied aspect of FA metabolism in PCa, β -oxidation, to evaluate its therapeutic potential.
We showed previously (22) , as have others (24, 43) , that PCa cells exhibit increased FAO compared to prostate epithelial PNT-1 cells, or benign epithelial cells BPH-1 and WPMY-1.
This metabolic phenotype is a vulnerability for PCa cells (21, 23, 25) . FAO inhibitors such as etomoxir, perhexiline or ranolazin inhibited tumor growth in vitro and in vivo (21, 23, 25) and sensitized cells to ENZ treatment (23, 25) . However, all of these studies were undertaken using immortalized cell line models of PCa, and as cancer metabolism is markedly influenced by the tumor microenvironment (44) (45) (46) , employing preclinical models and primary tissues that retain the complexity of this microenvironment as a stepping stone to clinical trials may accelerate clinical translation and avoid futile targeting strategies or agents. In this study, we evaluated the efficacy of the FAO inhibitor, etomoxir, using our established PDE model.
Remarkably, etomoxir inhibited effectively cell proliferation in PDEs (Figure 1A) , strengthening the case that targeting FA oxidation may be a promising clinical strategy.
Interestingly, etomoxir was more potent in inhibition of cell proliferation in PDEs than in vitro 2-dimensional growth of LNCaP cells, emphasising that in vitro models based on 2D cultured cells alone are sub-optimal when evaluating anti-metabolism agents. This problem is compounded by the fact that standard growth media is rich in sugar and proteins, but contains low levels of lipids. As the clinical development of etomoxir was terminated due to severe hepatotoxicity associated with treatment (47), we sought to identify new β -oxidation targets in PCa. As DECR1 is an androgen-repressed gene, its expression increases after castration or treatment with anti-androgens and is hypothesized to maintain tumor cell survival under castration conditions. Androgen-repressed genes are markedly understudied compared with androgen-induced genes, despite the fact that they possibly mediate adaptive survival pathways when androgen signalling is perturbed, and have already yielded novel therapeutic targets (48, 49) .
Surprisingly, the biological role of DECR1 in PCa has never been examined, and very little is known about its function in other cancers. Human DECR1 deficiency is lethal, with patients exhibiting hypocarnitinemia, decreased cellular oxygen consumption, increased lactic acidosis, and unusual accumulation of FA intermediates in urine and blood due to incomplete β -oxidation (50, 51) . DECR1-null mice exhibit impaired lipid metabolism, hypoglycaemia and activation of ketogenesis, and cold intolerance (52, 53) . These phenotypes highlight the critical role of DECR1 in lipid metabolism. We confirmed the metabolic activities of DECR1
in PCa cells using a panel of metabolomic and lipidomic analyses. DECR1 knockdown increased levels of certain acylcarnitine species, indicating inhibition of β -oxidation. These results are consistent with previous studies reporting acylcarnitine accumulation in Decr1 -/mice and DECR1-deficient patients (50, 52) . We showed that DECR1 knockdown selectively inhibited PUFA catabolism, accompanied by an increase in glycolysis rate, which is also consistent with previous reports of FAO inhibition or impaired mitochondrial function leading to enhanced glucose uptake and glycolysis (43, 51) . Lipidomic analysis showed that DECR1 knockdown increased the abundance of PUFAs and certain lipids, particularly PE and PI phospholipid species, accompanied by increased levels of mitochondrial oxidative stress and particularly lipid peroxidation. In contrast to MUFAs, PUFAs are highly susceptible to peroxidation, thereby enhancing free radical generation and accumulation of toxic lipid peroxides (54, 55) . Consistent with a role for PUFA oxidation in DECR1 function, ectopic DECR1 overexpression decreased mitochondrial oxidative stress. An important cellular protective response to excess intracellular lipid peroxides is the induction of ferroptosis, an iron-dependent form of cell death that is triggered by lipid peroxidation. Here, we show that the ferroptosis inhibitor ferrostatin or the ferroptosis inducer erastin abolished and augmented the effect of DECR1 on PCa cell death, respectively. These findings support a mechanism by which DECR1 knockdown-induced cell death is a ferroptosis-mediated process caused by PUFA accumulation. It is therefore possible that PCa cells commonly select for DECR1 overexpression, not only to enhance ATP production to fulfil energy requirements, but also to protect cells from the tumoricidal effects of excess PUFAs.
PUFAs are essential FAs that cannot be synthesized in mammals and are only obtained from the diet. Dietary fat not only promotes obesity, but also PCa progression and disease aggressiveness. Several preclinical PCa studies have compared high-fat (or Western-style diets) versus low fat diet and reported that the former promotes AKT and ERK activity, tumor growth, tumor incidence in genetically engineered/transgenic mouse models, tumor progression to CRPC and metastasis (reviewed in (56)). Clinical case-control studies indicated saturated fat is associated with an increased risk of advanced PCa (57) (58) (59) (60) . Several underlying mechanisms were proposed to explain the association between dietary fat and PCa development and progression, including growth factor signalling (such as IGF-1), inflammation, and endocrine modulation (56) . While the evidence supporting the negative impacts of saturated dietary FAs are more consistent, the effect of dietary PUFAs on PCa aggressiveness remains inconclusive and differences between omega-3 and omega-6 have been reported (57, 58, 61, 62) . In contrast to omega-3 PUFAs, which are reported to inhibit PCa progression (63), omega-6 PUFAs (64,65), and higher omega-6/omega-3 PUFA ratio, increase PCa risk (66, 67) . Dietary intervention by decreasing total fat intake and increasing omega-3 PUFAs was found to improve PCa survivorship (68) (69) (70) (71) . It is unclear whether there is a preference for n-6 or n-3 PUFA β -oxidation in PCa cells, however both require DECR1
for complete β -oxidation.
Although FAO is a complex process that requires the activity of several enzymes, to date the entire focus of drug development strategies has been inhibitors against CPT1, the ratelimiting step of FA β -oxidation. CPT1 is responsible for synthesising fatty acyl-carnitines from fatty acyl-CoAs which are then transported from the cytoplasm into the mitochondria by carnitine acylcarnitine translocase for subsequent processing then entry into the β -oxidation pathway. Even though targeting CPT1 is efficient in inhibiting FA β -oxidation, the clinical use of CPT1 inhibitors is challenging. Based on our current findings, we propose that DECR1
is an attractive alternative target to CPT1. CPT1 inhibition would suppress β -oxidation of all long FA species (saturated FA, MUFA and PUFA), whilst in contrast DECR1 is specific for PUFA. Homozygous CPT1 deficiency, of either the liver or muscle isoform, is lethal in mice (72-74), but Decr1 −/− mice are viable, and clinical symptoms arose only after metabolic stress (52, 53) . The marked overexpression of DECR1 in prostate tumors across multiple clinical cohorts, potentially coupled to PUFA-related dietary interventions, may lend further selectivity to targeting strategies. Of note, the crystal structure of DECR1 active site has been solved (35) , and thus developing DECR1 inhibitors is feasible.
In summary, herein we strengthen the evidence base for the critical importance of FAO and, specifically, PUFA oxidation in PCa, thereby identifying a promising new therapeutic candidate, DECR1.
Materials and Methods
Meta-Analysis of Lipid Metabolism Genes
Individual RNA-sequencing (RNA-seq) datasets composed of matched normal versus tumor prostate cancer patient tissue samples were acquired and are listed as follows: (1) 
Clinical Datasets
Transcriptomic data was downloaded from The Cancer Genome Atlas (TCGA) data portal, cBioPortal (31), and GEO; GSE21032 (76); GSE35988 (77); GSE6099 (78); GSE16560 (79) .
Proteomics data was extracted from Iglesias-Gato et al. (19) .
Cell lines and tissue culture
The human normal prostate epithelial cell lines PNT1 and PNT2, and prostate carcinoma cells LNCaP, VCaP, and 22RV1 were obtained from the American Type Culture Collection Supplementary Table 1 .
Primers were obtained from Sigma-Aldrich and their sequences are detailed in Supplementary Table 2 and 3 .
Ex Vivo culture of human prostate tumors
Patient derived-explant culture was carried out according to techniques established in our laboratory and as described previously (81) (82) (83) was added into each well and the tissues were cultured in 5% CO 2 in a humidified atmosphere at 37°C for 48 hours, then snap frozen in liquid nitrogen and stored at −80°C, or formalin-fixed and paraffin-embedded.
Immunohistochemistry (IHC)
Paraffin-embedded tissue sections (2-4µm) were deparaffinized in xylene, rehydrated through graded ethanol, and blocked for endogenous peroxidase before being subjected to heat-3 0
induced epitope retrieval (81) . IHC staining was performed using DECR1 (HPA023238, Sigma Aldrich, diluted 1:500) antibody and the 3,3′-Diaminobenzidine (DAB) Enhanced Liquid Substrate System tetrahydrochloride (Sigma Aldrich) as described previously (81) .
Intensity of DECR1 immunostaining was measured by video image analysis (81) .
Western Blotting
Protein lysates were collected in RIPA lysis buffer (10 mM Tris, 150mM NaCl, 1mM EDTA, 1% Triton X-100, 10% protease inhibitor). Western blotting on whole cell protein lysates were performed as previously described (81) . Cell Fractionation. Protein lysates from each subcellular fraction (cytoplasm, mitochondria, and nucleus) were obtained from PNT1 and LNCaP cells using the cell fractionation kit (Abcam, VIC, Australia) according to the manufacturer's protocol.
Quantitative Real-Time PCR (qPCR)
RNA was extracted from cells using the RNeasy RNA extraction kit (Qiagen), followed by the iScript TM cDNA Synthesis kit (Bio-Rad, NSW, Australia). qPCR was performed with a 1:10 dilution of cDNA using SYBR Green (Bio-Rad) on a CFX384 Real-Time System (Bio-Rad). Relative gene expression was calculated using the comparative Ct method and normalized to the internal control genes GUSB and L19 for prostate cancer cells and LNCaPderived tumors, or TUBA1B, PPIA and GAPDH for PDEs.
Analysis of published ChIP-seq data
AR ChIP-seq data from published external datasets, GSE56288 (clinical specimens; 7 normal prostate and 13 primary tumors) (84) and GSE55064 (VCaP cell line; Veh, DHT treated, MDV3100 treated and Bicalutamide treated) (85) were obtained from GEO and visualized using the Integrated Genome Browser (IGV).
Chromatin Immunoprecipitation (ChIP) 1
LNCaP cells were seeded at 3 × 10 6 cells/plate in 15 cm plates in RPMI-1640 medium containing 10% DCC-FBS for 3 days, then treated for 4 hours with 10 nM DHT or Vehicle (ethanol). AR ChIP was performed as described previously (86) .
Transient RNA interference
The human DECR1 ON-TARGET plus small interfering RNAs (siRNAs) and control siRNA (D-001810-01-20 ON-TARGET plus Non-targeting siRNA #1) were purchased from Millennium Science (VIC, Australia). Four siRNA were tested and the two most effective were selected for our experimentation: siDECR1-1 (J-009642-05-0002) and siDECR1-2 (J-009642-06-0002). The siRNAs at a concentration of 5 nM were reverse transfected using Lipofectamine RNAiMAX transfection reagent (Invitrogen, VIC, Australia) according to the manufacturer's protocol. DECR1 downregulation (>80%) was confirmed on mRNA and protein levels. according to the manufacturer's protocol. The sequence of the DECR1 shRNA and the hDECR1 is depicted in Figure S5 .
Generation of stable shDECR1 and hDECR1 LNCaP cells
Functional Assays
Cell Viability. Cells were seeded in triplicates in 24-well plates at a density of 3.0 × 10 4 -6 × 10 4 cells/well and reverse transfected with siRNA overnight. Cells were manually counted using a hemocytometer 96 hours post-siRNA knockdown and viability was assessed by Trypan Blue exclusion as described previously (81) . 3D Spheroid Growth Assay. LNCaP and 22RV1 cells were transfected with siRNA in 6-well plates for 48 hours. Cells were collected and prepared at a concentration of 7.5 × 10 4 cells/ml.
Cell suspensions (1500 cells in 20 µl) were pipetted onto the inside of a petri dish lid, and 15ml of PBS was added to the dish to prevent the drops from drying. The petri dishes were reassembled and incubated at 37°C for 5 days. Photos of the formed spheres were captured, and the sphere volume was determined using ReViSP software (87) . 
Seahorse Extracellular Flux Analysis
Metabolomics
LNCaP cells were transfected with siRNA for 96 hours in no glucose medium (containing 10% FBS) supplemented with 2.5 mM glucose in 6-well plates. Cells were washed with 1 ml of 37°C Milli-Q water on the shaker for 2 seconds. The plate was placed in sufficient volumes of liquid nitrogen, enough to cover the surface of the plate and was briefly stored on dry ice. 600 µl of ice cold 90% 9:1 methanol:chloroform (MeOH:CHCl 3 ) extraction solvent containing the internal standards (0.5 µl/samples) was added onto each well and allowed to incubate for 10 minutes. Cells were collected into 1.5 ml Eppendorf tubes, incubated on ice for 5 minutes, and centrifuged at 4°C for 5 minutes at 16,100g. The supernatant was then transferred into a fresh 1.5 ml Eppendorf tube and allowed to dry in a Speedvac. Dried samples were derivatised with 20 µl methoxyamine (30 mg/ml in pyridine, Sigma Aldrich) and 20 µl N,O-Bis(trimethylsilyl)trifluoroacetamide (BSTFA) + 1% Trimethylchlorosilane (TMCS). The derivatised samples were analysed using GC QQQ targeted metabolomics as described in (88).
Mitochondrial ROS Measurement
LNCaP cells were transfected with siRNA for 96 hours in 6-well plates. Cells were collected into fluorescence-activated cell sorting (FACS) tubes and stained with 2.5 mM of MitoSOX TM Red stain (Thermo Fisher Scientific, VIC, Australia) for 30 minutes in a 37°C water bath. Cells were centrifuged at 1,500rpm for 5 minutes, washed twice with 500 µl of PBS, and resuspended in 500 µl of pre-warmed PBS before the samples are read on a BD FACSymphony TM flow cytometer.
Acyl-Carnitine Measurement
Total lipids were extracted from cells using two-phase extraction with methyl-tert-butyl-ether (MTBE)/methanol/water (10:3:2.5, v/v/v) (89) . Cell pellets were frozen in 8:1 methanol/water prior to extraction with the above solvent mixture; for cell culture supernatant An exclusion list of background ions was used based on a solvent blank. TraceFinder v5.0 (Thermo Fisher) was used for peak detection and integration, based on exact precursor ion mass (m/z tolerance 4 ppm) and m/z 85.0 acylcarnitine product ion. Peak areas were normalised to the D3-palmitoylcarnitine internal standard.
In Vivo Experiment
LNCaP cells (5 × 10 6 cells in 50μL 10% FBS/RPMI 1640 medium) were co-injected subcutaneously with 50μL Matrigel in 6-week-old Nod Scid Gamma male mice (Bioresource Facility, Austin Health, Heidelberg, Australia). When tumors reached ~200mm 3 , mice were randomized in different therapy groups. One group was left untreated (n = 5), one group was treated with vehicle control (10% DMSO/PBS; n = 5), one group was treated with enzalutamide (10 mg/kg MDV3100 in 10% DMSO/PBS) and one group was castrated by surgical castration under isofluorane anaesthesia (n = 9). Five of the ten castrated mice were then treated daily with enzalutamide (10 mg/kg MDV3100 in 10%DMSO/PBS) by oral gavage for 7 days. Enzalutamide therapy of castrated mice started five days after surgery.
In a second study, DECR1 stable knockdown cells (shDECR1) or negative control cells (shControl) (5 × 10 6 cells in 50μL 10% FBS/RPMI 1640 medium) were co-injected subcutaneously with 50μL matrigel in 6-week-old Nod Scid Gamma male mice. Tumours were measured using a calliper and their volumes were calculated using the formula length × width 2 /2.
For both studies, tumours were excised and half was snap frozen for RNA extraction while the other half was formalin fixed and paraffin embedded.
Statistical Analysis
Results are reported as mean ± S.E.M. Statistical analysis was performed using GraphPad Prism (V7.0 for Windows). Differences between treatment groups were compared by T-test or one-way ANOVA followed by Tukey or Dunnett post hoc test. Significance is expressed as *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
